Skip to main content
CPC 2023 Main banner

Full Schedule

  1. Home
  2. Full Schedule

Full Schedule

  • Friday, October 6, 2023
  • 8:00 AM – 9:00 AM ET
    Breakfast Networking Session with Complimentary Headshot Session
    Socialize with fellow attendees over breakfast to kick off the event. Complimentary headshots from a professional photographer to update your professional profile will be available.
  • 9:00 AM – 9:15 AM ET
    Journal of Clinical Pathways: Best of 2023 Presentation

    Presenter: Winston Wong, PharmD – W-Squared Group

    The Editor-in-Chief of the Journal of Clinical Pathways (JCP) Winston Wong, PharmD will review the Journal’s most important articles from the past year. JCP features peer-reviewed education on the development, implementation, and evaluation of clinical pathways. Relevant topics include comparative-effectiveness research; big data analytics; methods in clinical pathway development; optimization of clinical pathway implementation and adherence; health economics and outcomes research; patient-centered outcomes; and alternative payment and value-based care models.
  • 9:25 AM – 9:30 AM ET
    Welcome Remarks
  • 9:30 AM – 10:05 AM ET
    Session 1: CPC + CBEx: A New Agenda in Oncology

    Moderator: Gordon Kuntz – Kuntz Consulting

    Panelist: Ronald Barkley, MS, JD – Cancer Center Business Development Group

    Panelist: Lee Blansett, MBA, BSC – HMP Market Access

    Panelist: Stephen B. Edge, MD, FACS, FASCO – Roswell Park Comprehensive Cancer Center

    Panelist: John E. Hennessy, MBA – Valuate Health Consultancy

    Panelist: Deirdre Saulet, PhD – Carrum Health

    Panelist: Mahek A. Shah, MD, MBA, MS – Harvard University and WTM Advisors

    Bringing together the best of pathways and oncology business expertise. Lee Blansett will present critical trends from the IDN, Community Oncology, Payer and Pathways Reports that are driving the current oncology marketplace. Following his presentation, a panel of pathways and oncology business leaders will highlight their key takeaways and discuss where we will dive deeper throughout the event.
  • 10:05 AM – 10:45 AM ET
    Session 2: Updates from Washington

    Moderator: Barbara McAneny, MD – New Mexico Oncology Hematology Consultants & Former President AMA

    Panelist: Nicolas Ferreyros – Community Oncology Alliance (COA)

    Panelist: Frederick M. Schnell, MD, FACP – National Cancer Treatment Alliance/Community Oncology Alliance

    Review the latest developments from Capitol Hill and HHS and show how recent changes will affect community oncology practice.
  • 10:45 AM – 11:45 AM ET
    Session 3: Treating the Individual

    Moderator: Mahek A. Shah, MD, MBA, MS – Harvard University and WTM Advisors

    Panelist: Mary E. Cooley, PhD, RN, FAAN – Dana-Farber Cancer Institute

    Panelist: David F. Lobach, MD, PhD, MS – Elimu Informatics

    Panelist: Ray Page, DO, PhD, FACOI, FASCO – The Center for Cancer and Blood Disorders

    Dr. Ray Page will discuss the intersection of personalized medicine and treatment pathways and how they can combine to drive the best outcomes in patients. Dr. Mary Cooley and Dr. David Lobach will present their work on a clinical decision-support tools for the management of uncontrolled cancer symptoms.
  • 11:45 AM – 12:30 PM ET
    Session 4: HER2-Positive Breast Cancer: Establishing Proper Sequences Through Clinical Pathways

    Moderator: Stephen B. Edge, MD, FACS, FASCO – Roswell Park Comprehensive Cancer Center

    Presenter: Sayeh Lavasani, MD, MS, FRCPC – UC Irvine Cancer Center

    After completing this activity, learners will be able to • Assess efficacy and safety of current and recently approved agents to incorporate into second- and third-line treatment of HER2-positive breast cancer • Describe the challenges of creating and implementing clinical pathways for HER2-positive breast cancer • Develop clinical pathways for HER2-positive breast cancer to optimize evidence-based and cost effective second- and third- line treatments
  • 12:40 PM – 1:40 PM ET
    Non-Accredited Featured Partner Showcase

    Moderator: Rushir Choksi, MD – UPMC Hillman Cancer Center

    Presenter: Ed Rodgers – ClinicalPath

    Presenter: Joe Baffone – Annexus Health

    Presenter: Susan Weidner – IntrinsiQ

  • 1:50 PM – 2:20 PM ET
    Session 5: Time to Treat: Why it Matters and How Pathways Can Help

    Moderator: Mahek A. Shah, MD, MBA, MS – Harvard University and WTM Advisors

    Presenter: Dennis R. Holmes, MD, FACS – XpediteMD, Inc.

    Dr. Dennis Holmes will connect delays between diagnosis and treatment to their effects on patient outcomes. Then he will explore ways to close the diagnosis-treatment gap, including effective use of pathways.
  • 2:20 PM – 3:50 PM ET
    Session 6: The Hunt for Value in Value-Based Cancer Care: How to Meet Stakeholders' Evolving Demands

    Moderator: Deirdre Saulet, PhD – Carrum Health

    Panelist: Afsaneh Barzi, MD, PhD – AccessHope

    Panelist: Ronda Bowman, MHA, RN, OCN – ASCO Care Delivery

    Panelist: David Eagleton – Oncology Care Partners

    Panelist: Andrew Hertler, MD, FACP – Evolent

    Panelist: Harlan Levine, MD – City of Hope

    Panelist: Barry Russo, MBA – The Center for Cancer and Blood Disorders

    Panelist: Stephen Schleicher, MD, MBA – Tennessee Oncology

    Panelist: Frederick M. Schnell, MD, FACP – National Cancer Treatment Alliance/Community Oncology Alliance

    Our keynote opening will provide insights into today’s top market dynamics impacting cancer care and the key trends to keep your eye on in the future. • Learn why self-insured employers are increasingly focused on improving their cancer care benefits and the impact on other stakeholders across the industry • Understand the complexities of the Medicare Advantage market and what its growth means for practice leaders and physicians leading the way, and their motivations
  • 3:50 PM – 4:00 PM ET
    Break
  • 4:00 PM – 5:00 PM ET
    Session 7: Healthcare Industry Consolidation: The Impact on Cancer Care and Strategic Partnerships

    Moderator: Michael Kolodziej, MD – ADVI

    Panelist: Ronald Barkley, MS, JD – Cancer Center Business Development Group

    Panelist: Harlan Levine, MD – City of Hope

    Panelist: Barbara McAneny, MD – New Mexico Oncology Hematology Consultants & Former President AMA

    Panelist: Todd Schonherz – American Oncology Network

    Panelist: Adria Warren, JD – Foley & Lardner

    • Overview of the current consolidation of the healthcare industry, the major players and disruptors leading the way, and their motivations • Learn how leading providers are developing strategies to respond, including affiliation models
  • 5:00 PM – 6:00 PM ET
    Exhibit Hall
  • Saturday, October 7, 2023
  • 8:00 AM – 9:00 AM ET
    Breakfast
  • 8:45 AM – 8:50 AM ET
    Opening Remarks
  • 8:50 AM – 9:50 AM ET
    Session 8: Cancer Care at Home: Opportunities, Risks, and How to Prepare

    Moderator: John E. Hennessy, MBA – Valuate Health Consultancy

    Panelist: Aaron Gerber, MD, MBA – Reimagine Care, Inc.

    Panelist: Raj Hazarika, MD – Point32 Health

    Panelist: Barbara McAneny, MD – New Mexico Oncology Hematology Consultants & Former President AMA

    Panelist: Barry Russo, MBA – The Center for Cancer and Blood Disorders

    Panelist: Lindsey Zinck, PhD RN OCN NEA-BC – Univ Penn Medicine, Abramson Cancer Center

    • Learn about the current status of home-based cancer care • Consider the evolving business case, including the current value proposition, service limitations, and potential future opportunities
  • 9:50 AM – 10:50 AM ET
    Session 9: AI in Cancer Care: Separating Fact from Fiction

    Moderator: Ira Klein, MD, MBA – Tempus Labs

    Panelist: James Hamrick, MD – Flatiron Health

    Panelist: Ed Rodgers – ClinicalPath

    Panelist: Will Shapiro – Flatiron Health

    Panelist: Zachary Taft – Memorial Sloan Kettering Cancer Center

    Panelist: Amy Valley, PharmD – Cardinal Health Specialty Solutions

    • Understand the use case for AI in cancer care today, and study existing uses in oncology operations and care • Learn key principles for evaluating vendors and the legitimacy of AI-enabled technologies • Envision the future and how AI may significantly impact the delivery of care, including clinical pathways
  • 10:50 AM – 11:20 AM ET
    Break
  • 11:20 AM – 12:20 PM ET
    Session 10: Reimagining Clinical Trials in the Community Setting

    Moderator: Nina Chavez, MBA – Flatiron Health

    Panelist: Ivy Altomare, MD – Flatiron Health

    Panelist: Sibel Blau, MD – Northwest Medical Specialties / QCCA Network / Exigent Research

    Panelist: Lindsay Kehoe, MS, CGC – Duke University/Clinical Trial Transformation Initiative (CTTI)

    Panelist: Seo Yoon, MPH – Memorial Sloan Kettering Cancer Center

    • The current state of clinical research in community oncology • Increasing the reach and access of clinical trials into the community • How technologies and new models are changing clinical research
  • 12:20 PM – 12:50 PM ET
    Session 11: New Dimensions in Comprehensive Genomic Testing

    Moderator: Alan J. Balch, PhD – Patient Advocate Foundation

    Presenter: Eric Severson, MD, PhD, MMSc – Labcorp Oncology

    As genetics takes a greater role in the treatment of a wide spectrum of cancers, this session will examine genomic testing’s role in comprehensive oncology pathways.
  • 1:00 PM – 2:15 PM ET
    Non-Accredited Featured Partner Showcase
  • 2:20 PM – 3:05 PM ET
    Session 12: Utility of Clinical Pathways for Multiple Myeloma: Navigating Updates in Guidelines and Care

    Moderator: Frederick M. Schnell, MD, FACP – National Cancer Treatment Alliance/Community Oncology Alliance

    Presenter: Prashant Kapoor, MD – Mayo Clinic

  • 3:05 PM – 3:35 PM ET
    Exhibit Hall
  • 3:35 PM – 4:55 PM ET
    Session 13: Scaling Precision Medicine Expertise for Equitable Cancer Care: Breaking Barriers, Advancing Patient Outcomes

    Moderator: Ivy Altomare, MD – Flatiron Health

    Panelist: Debyani Chakravarty, PhD – Memorial Sloan Kettering Cancer Center

    Panelist: James Hamrick, MD – Flatiron Health

    Panelist: John W. Sweetenham, MD, FACP, FRCP, FASCO – UT Southwestern Simmons Comprehensive Cancer Center

    Precision medicine has revolutionized cancer care, but ensuring widespread access and high-quality implementation across the care continuum remains a challenge. In this session, we will explore strategies to scale precision medicine expertise, addressing barriers and highlighting resources to deliver personalized care to all patients.
  • 4:55 PM – 5:40 PM ET
    Session 14: Evidence-Based Approaches to Clinical Pathway Development for Metastatic Urothelial Cancer

    Moderator: Wui-Jin Koh, MD – National Comprehensive Cancer Network

    Presenter: Stephanie A. Berg, DO – Dana-Farber Cancer Institute , Lank Center for Genitourinary Oncology

  • 5:40 PM – 6:30 PM ET
    Exhibit Hall Reception
  • Sunday, October 8, 2023
  • 8:30 AM – 9:00 AM ET
    Breakfast
  • 9:00 AM – 9:10 AM ET
    Opening Remarks
  • 9:10 AM – 10:10 AM ET
    Session 15: Real-World Evidence and Pathways

    Moderator: Susan Carr, MPH – Johns Hopkins School of Medicine

    Presenter: Channing J. Paller, MD – Johns Hopkins School of Medicine

    Presenter: Lillie D. Shockney, RN, BS, MAS, HON- ONN-CG – Johns Hopkins School of Medicine

    Join an in-depth case study of how using real-world evidence improves clinical pathways, streamlines clinical operations, and benefits patient outcomes.
  • 10:10 AM – 10:55 AM ET
    Session 16: The Evolving Role of Cost in Pathways: Cost of Care, Cost Avoidance, and Patient Costs

    Moderator: John E. Hennessy, MBA – Valuate Health Consultancy

    Panelist: Chevon Rariy, MD – Oncology Care Partners

    Panelist: Ed Rodgers – ClinicalPath

    Panelist: Mahek A. Shah, MD, MBA, MS – Harvard University and WTM Advisors

    An in-depth panel will investigate factors beyond drug costs that affect the bottom line and how pathways can effectively aid to manage these costs.
  • 10:55 AM – 11:30 AM ET
    Break
  • 11:30 AM – 12:15 PM ET
    Session 17: Pathway Use Beyond the Unidimensional Treatment Decision

    Moderator: Mahek A. Shah, MD, MBA, MS – Harvard University and WTM Advisors

    Presenter: Stephen B. Edge, MD, FACS, FASCO – Roswell Park Comprehensive Cancer Center

    A presentation on the use of clinical pathways in the real world.
  • 12:15 PM – 1:00 PM ET
    Session 18: Town Hall with Steering Committee

    Moderator: Gordon Kuntz – Kuntz Consulting

    Steering Committee Member: Ronald Barkley, MS, JD – Cancer Center Business Development Group

    Steering Committee Member: Alan J. Balch, PhD – Patient Advocate Foundation

    Steering Committee Member: Stephen B. Edge, MD, FACS, FASCO – Roswell Park Comprehensive Cancer Center

    Steering Committee Member: Wui-Jin Koh, MD – National Comprehensive Cancer Network

    Steering Committee Member: Deirdre Saulet, PhD – Carrum Health

    Steering Committee Member: Frederick M. Schnell, MD, FACP – National Cancer Treatment Alliance/Community Oncology Alliance

    Steering Committee Member: Mahek A. Shah, MD, MBA, MS – Harvard University and WTM Advisors

    Join the Clinical Pathways Steering Committee as they gather to answer your outstanding questions from the previous three days of presentations.